.png)
Transgender Hair Loss: How Gender-Affirming Hormones Affect Your Hair and What Treatments Work
- Dr Heng Jiacheng
- 7d
- 7 min read
Written by Dr Heng Jiacheng, MBBS, Diploma in Aesthetic Medicine (AAAM)Associate Member, ISHRS · Member, AAHRS. Insights from a Singapore-based hair-loss physician
Hair loss is one of the most emotionally significant concerns for transgender and gender-diverse individuals and one that is pretty complex. Whether you are beginning testosterone therapy or have been on estrogen-based hormone therapy for years, understanding how hormones affect your scalp puts you in a far better position to protect your hair and take action early.
This article reflects how I approach hair loss in my own clinical practice, guided by the current prevailing evidence, the treatments and medications that have worked well for my patients, and where I believe hair supplements fit within a comprehensive treatment plan.
How Gender-Affirming Hormone Therapy Affects Hair
Hormones are the primary driver of hair loss patterns. This is true for cisgender people, and it is equally true for transgender individuals on gender-affirming hormone therapy (GAHT). The type of GAHT you are on determines your risk profile, and which treatments are actually going to work.
Transgender hair Loss in transmasculine Individuals Taking Testosterone
What testosterone does to your scalp
Testosterone therapy does not cause hair loss directly. The real culprit is dihydrotestosterone (DHT) -> a more potent androgen that testosterone is converted into by an enzyme called 5α-reductase, which is present in the hair follicles of the scalp.
For individuals with a genetic predisposition to androgenetic alopecia (AGA), DHT shrinks hair follicles over time, producing the classic male-pattern hair loss: a receding frontal hairline in an M-shape, and thinning at the crown (vertex). Mixed patterns can also occur. Some patients do experience female pattern type thinning (Note that it is a misnomer. Males can get female pattern thinning, females can get male pattern thinning)
The numbers are significant. Research tracking transgender men over 10 years found that approximately 33% developed mild alopecia and 31% developed moderate-to-severe alopecia after starting testosterone. A large cohort study of over 37,000 patients found that transmasculine individuals on GAHT had 2.5 times the rate of AGA compared to cisgender women, comparable to rates seen in cisgender men.
Hair loss typically begins 2–5 years after starting testosterone, though this varies. Importantly, the risk is not related to your testosterone dose, formulation, or route of administration but rather a family history of hair loss.
If you have a strong family history of male-pattern baldness on either side of your family, the conversation about hair loss prevention is worth having early, ideally before significant loss occurs.
Why DHT-blocking supplements are unlikely to be enough
This is one of the most important points to understand clearly. When your body is being supplemented with exogenous testosterone and converting it to DHT continuously, the hormonal load is substantial. Plant-based DHT blockers are unlikely to meaningfully counter this.
If you are experiencing hair loss on testosterone therapy, you need medication not just supplements.
Supplements may still be useful as an adjunct to correct deficiencies (iron, zinc, vitamin D, and ferritin are common in hair loss) or to support overall follicle health. But they cannot substitute for the pharmacological treatments below.
Treatment options for transmasculine individuals
The complexity here is real: the most effective treatments for AGA are antiandrogens, which can interfere with the masculinising effects of testosterone. Treatment timing therefore matters.
Within the first 2 years of testosterone therapy (when masculinisation is still developing):
Topical minoxidil 5%
Oral minoxidil, can go up to 2.5mg or 5mg depending on bodyweight
Low-level laser light therapy (LLLT), at least three times weekly: a non-pharmacological adjunct with reasonable supporting evidence; safe to use at any stage
After 2 years, or when masculinisation is well established:
Oral finasteride 1 mg daily: the first-line oral medication
It blocks the 5α-reductase enzyme that converts testosterone to DHT. May blunt some masculinising effects if used too early. Once physical changes (muscle mass, body fat redistribution, facial hair) are well established, the trade-off is generally more acceptable
Topical finasteride 0.25%:
second-line; lower systemic absorption reduces risk of interfering with masculinisation
Similar effects as per oral finasteride but costlier and more user dependent (ie works on areas that are applied)
Injectable dutasteride 0.5%: can be done via microneedling
Hair transplantation is also a meaningful option for transmasculine individuals. Beyond restoring density, a well-planned transplant can create a beard or masculinised hairline that serves as a significant gender-affirming outcome. Timing matters: it is generally advisable to stabilise hair loss medically before undergoing transplantation.
Transgender hair Loss in transfeminine Individuals Taking Estrogen and Antiandrogens
What feminising hormone therapy does to your scalp
Feminising GAHT, typically estradiol combined with an antiandrogen such as spironolactone or cyproterone acetate, works by blocking androgen receptors and suppressing testosterone production. This hormonal shift slows or stops the androgenic signalling that drives AGA.
For many transfeminine individuals, this means that feminising therapy itself will slow or stabilise hair loss. Some will experience partial regrowth, particularly in areas where follicles have not been permanently miniaturised. The first 3–12 months of feminising therapy typically bring decreases in facial and body hair growth and redistribution of fat mass.
That said, the picture is not entirely reassuring. A large cohort study found that transfeminine individuals on feminising GAHT still had a 1.9 times higher rate of AGA compared to cisgender women. Prior androgen exposure, particularly if years elapsed before starting feminising therapy, can leave lasting effects on follicle sensitivity.
The practical takeaway: if you are transfeminine and not experiencing significant hair loss, your current hormone therapy is likely doing meaningful protective work. Stopping estrogen therapy carries a risk of accelerating scalp hair loss. If you are still experiencing active hair loss despite feminising GAHT, additional treatment is warranted.
Treatment options for transfeminine individuals
Transfeminine patients have an important advantage: antiandrogen therapies are compatible with and often part of their feminising hormone regimen. There is no conflict between treating AGA and pursuing gender-affirming goals.
First-line options:
Spironolactone — already in use for many transfeminine patients as part of GAHT, contributes to AGA management at standard doses
Topical minoxidil 5% or Oral minoxidil — (to not exceed 2.5mg for concerns of unwanted hair growth)
Low-level laser light therapy (LLLT)
Step up management for more severe cases: Will require additional stronger DHT blockade.
Oral finasteride at higher doses (2.5 mg and above) — doses used in post-menopausal women as well.
Oral dutasteride 0.5 mg daily — blocks both isoforms of 5α-reductase (type I and II), producing a more complete DHT reduction than finasteride; a meaningful step up for resistant cases
Dutasteride mesotherapy — intradermal micro-injections of dutasteride directly into the scalp; delivers the medication locally with minimal systemic absorption; a newer but promising option for targeted DHT suppression at the follicle level
Hair transplantation is a powerful gender-affirming option for transfeminine individuals. Hairline feminisation, lowering the frontal hairline, softening the temples, and creating a rounder, more arched hairline shape, can have a profound impact on gender congruence and quality of life.
Important point to note: For transfeminine individuals planning for facial feminisation surgery (FFS). Do consider going for FFS first prior to staging a hair transplant. Most of the incisions for FFS are along the hairline. Having hair transplant after FFS procedure allows the surgeon to place grafts to cover up the FFS scar. Do note that its is preferred to stage the hair transplant at least 6 months to a year after the FFS procedure
As with transmasculine patients, medical stabilisation of hair loss prior to transplantation is advisable to protect the investment.
The Role of Hair Supplements in Exogenous hormone-Related Hair Loss
For both transmasculine and transfeminine individuals, the honest framing is this: medication is the mainstay of treatment for hormone-driven hair loss.
Supplementation plays a supportive, not a central, role.
What supplements cannot do is meaningfully override DHT-driven follicle miniaturisation in someone whose external hormonal environment continues to drive it. This is the key distinction to understand before spending money on supplements as a primary strategy.
Hair supplements role in transgender patients is an adjunct alongside your medical treatment correcting deficiencies that compound hair loss, and supporting the follicular environment so that your medications can do their job more effectively.
Roots² Androgenetic Alopecia Supplement
Roots² AGA protocol is developed specifically around the root causes of hair loss. Importantly, Roots² is designed to be used alongside medical treatment, not instead of it
One important note for individuals on testosterone: the Roots² AGA supplement contains saw palmetto and pumpkin seed extract, which have mild 5α-reductase inhibitory activity. While these are not pharmacologically equivalent to finasteride, anyone in the early stages of testosterone therapy (first 2 years) who is still establishing masculinisation should discuss this with their prescribing clinician before starting. For those past the 2-year mark or on a stable masculinisation regimen, the effect is unlikely to be clinically significant alongside ongoing testosterone therapy.
Key Takeaways
Transmasculine (Testosterone) | Transfeminine (Estrogen/Antiandrogens) | |
Primary driver of hair loss | DHT conversion from testosterone | Prior androgen exposure; incomplete DHT suppression |
Risk vs. cisgender men/women | 2.5× higher | 1.9× higher |
When does loss typically begin | 2–5 years after starting T | Variable; most likely predate transition |
First-line medication | Topical/oral minoxidil (early); finasteride after 2 years or completion of masculinisation | Spironolactone,cyproterone acetate, topical/oral minoxidil, finasteride, dutasteride |
Hair transplantation | Beard transplant; hairline masculinisation | Hairline feminisation |
Role of supplements | Adjunct; correct deficiencies | Adjunct; correct deficiencies |
This article is intended for informational purposes and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare provider familiar with transgender health.
References:
Pediatric Dermatology. 2021. Swink SM, Castelo-Soccio L.
The Journal of Clinical Endocrinology and Metabolism. 2017. Hembree WC, Cohen-Kettenis PT, Gooren L, et al.
Journal of the American Academy of Dermatology. 2023. Gao JL, Streed CG, Thompson J, Dommasch ED, Peebles JK.Review
Clinical and Experimental Dermatology. 2023. Tang GT, Zwickl S, Sinclair R, Zajac JD, Cheung AS.
The Cochrane Database of Systematic Reviews. 2020. Haupt C, Henke M, Kutschmar A, et al.
Comments